Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

PharmAsia News Notable Notes: Will Rising Rupee Continue To Hold Back Retooled Indian Pharma Firms?

This article was originally published in PharmAsia News

Executive Summary

NEW DELHI - A confluence of new revenues from contract research and manufacturing services, in-license deals from multinational drug firms, vigorous efforts to discover new drugs, a slew of successful patent challenges and an upbeat outlook for generic drug demand, make leading Indian pharma companies attractive investments in a downbeat global economy, according to a 55-page report by IDFC-SSKI, the investment banking subsidiary of Mumbai-based Infrastructure Development Finance Company

Table

View full table

Related Content

Scrip
Scrip
Tags:
Latest Headlines

Gilead Doesn’t See Big M&A In Near-Term, But Eyes Next-Gen Cell Therapies

BMS Will Cut $1.5bn And 2,200 Jobs To Reinvest In Needed Growth

AbbVie Claims Rinvoq Superiority To Dupixent In AD

Merck Investors Keeping A Close Watch On Winrevair Uptake

See All
UsernamePublicRestriction

Register

SC068099

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By